News Interpace Biosciences, Inc.

Equities

IDXG

US46062X3035

Market Closed - OTC Markets Other stock markets 01:21:55 2024-05-10 pm EDT			5-day change	1st Jan Change
1.45 ^USD	+3.57%		+2.84%	+34.26%

May. 09	Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 07	Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $10.3M	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Interpace Biosciences Announces First Quarter 2024 Financial and Business Results	May. 09	AQ
Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $10.3M	Mar. 07	MT
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results	Mar. 07	AQ
Interpace Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Interpace Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
Robert Gorman Provides Notice to Interpace Biosciences, Inc. of His Resignation as A Director and as Chairman of the Board, Including as A Member of the Board?s Regulatory Compliance Committee	Dec. 12	CI
Interpace Biosciences, Inc. Announces Resignation of Edward Chan as Class II Director	Nov. 16	CI
Interpace Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results	Nov. 08	AQ
Interpace Biosciences, Inc. Enters Amendment to Loan Security Agreement with Broadoak Fund V, L.P	23-10-27	CI
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results	23-08-09	AQ
Interpace Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Interpace Biosciences, Inc. Appoints Christopher Mccarthy as Chief Financial Officer	23-08-02	CI
Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement	23-07-10	AQ
Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023	23-06-05	AQ
Interpace Biosciences, Inc. Expects to Stop Offering Pancragen Test Due to CMS Decision to End Reimbursement as of July 17, 2023	23-06-05	CI
Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q1 Revenue $9.8M	23-05-12	MT
Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results	23-05-12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Interpace Biosciences, Inc.

Equities

IDXG

US46062X3035

Summary

Filters